Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Liabilities and Shareholders Equity (2019 - 2025)

Goldenwell Biotech's Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $220410.0 for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 22.84% year-over-year to $220410.0; the TTM value through Sep 2025 reached $887812.0, up 10.03%, while the annual FY2024 figure was $224192.0, 1.71% down from the prior year.
  • Liabilities and Shareholders Equity reached $220410.0 in Q3 2025 per GWLL's latest filing, down from $251295.0 in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $509176.0 in Q2 2021 to a low of $179432.0 in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $278007.5, with a median of $228094.0 recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 93.92% in 2021, then plummeted 46.11% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $460979.0 in 2021, then tumbled by 46.11% to $248400.0 in 2022, then dropped by 8.17% to $228094.0 in 2023, then decreased by 1.71% to $224192.0 in 2024, then dropped by 1.69% to $220410.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Liabilities and Shareholders Equity are $220410.0 (Q3 2025), $251295.0 (Q2 2025), and $191915.0 (Q1 2025).